In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Pharmaceutical
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
Pharmaceutical
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Pharmaceutical
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
Pharmaceutical
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Pharmaceutical
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Pharmaceutical
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Pharmaceutical
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Pharmaceutical
A JAMA Oncology investigation has looked into the whether prescriptions for semaglutide are associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes or patients who are overweight or obese. 5 July 2024
Pharmaceutical
Novartis, Pfizer, Otsuka and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. 5 July 2024
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca’s Tagrisso (osimertinib) has won a new approval in the European Union (EU). 5 July 2024
Pharmaceutical
The Russian pharmaceutical company Polysan will build one of the largest drugmaking facilities in the North-West of Russia, that will be located on the Sofiysky industrial park in St Petersburg. 5 July 2024
Pharmaceutical
Chennai, India-based Orchid Pharma has announced the launch of its new drug - cefepime-enmetazobactam. 4 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
New Jersey, USA-based biopharma firm Insmed (Nasdaq: INSM) has revealed additional positive outcomes from its Phase III ASPEN study of brensocatib. 4 July 2024
Pharmaceutical
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for tazemetostat for the treatment of adult patients with relapsed or refractory (R/R ) follicular lymphoma (FL) has been accepted for review and granted Priority Review in China. 4 July 2024
Pharmaceutical
A survey of British voters ahead of Thursday’s general election has revealed just how much importance they attach to the issue of access to medicines. 3 July 2024
Pharmaceutical
Pentixapharm has announced the acquisition of the target discovery business of fellow German firm Glycotope. 3 July 2024
Pharmaceutical
Annovis Bio (NYSE: ANVS), a late-stage drug developer, has announced new data from its Phase III study of Parkinson’s candidate buntanetap. 3 July 2024
Pharmaceutical
Oxford, UK-based ThirtyFiveBio, a company specializing in GPR35 inhibitors for gastrointestinal diseases, has announced receipt of a grant from Innovate UK. 2 July 2024
Pharmaceutical
Cambridge, UK-based Mission Therapeutics, a clinical-stage biotech, has received $5.2 million in funding from The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK. 2 July 2024
Pharmaceutical
China’s Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved Japanese pharma major Astellas’ Xtandi (enzalutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). 2 July 2024
Pharmaceutical
Pierre Fabre revealed that the European Commission (EC) has authorized the marketing of its Obgemsa (vibegron) for the symptomatic treatment of overactive bladder syndrome in adults. 2 July 2024
Pharmaceutical
US pharma major Eli Lilly has followed up last year’s $1.4 billion acquisition of radiopharmaceuticals firm POINT Biopharma Global with another deal in the field. 2 July 2024
Pharmaceutical
Spanish plasma-based medicines producer Grifols announced the expected launch in the first quarter of 2025 for Yimmugo. 2 July 2024
Pharmaceutical
In the USA, two New Drug Applications (NDA) for crinecerfont have been accepted by the US regulator, and will be considered under the Priority Review scheme. 1 July 2024
Pharmaceutical
NeuroSense Therapeutics (Nasdaq: NRSN), a late-clinical stage biotech firm, has announced significant findings from its 12-month Phase IIb PARADIGM study. 1 July 2024
Pharmaceutical
A co-development deal between Finland’s Orion Corporation (HEL: ORNAV) and Merck & Co (NYSE: MRK) has been upgraded to an exclusive global licensing agreement. 1 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze